Literature DB >> 18948976

E-clonal antibodies: selection of full-length IgG antibodies using bacterial periplasmic display.

Yariv Mazor1, Thomas Van Blarcom, Brent L Iverson, George Georgiou.   

Abstract

Here we describe a protocol for the selection of full-length IgG antibodies from repertoires displayed on Escherichia coli. In the method described here, full-length heavy and light chains are assembled in the periplasm into aglycosylated IgGs that are fully functional for antigen binding. Expression of an inner membrane-tethered Fc-binding protein is used to capture the IgG molecules and anchor them to the cell. Following outer-membrane permeabilization, fluorescently labeled ligand-binding library clones are selected by multiple rounds of fluorescence-activated cell sorting. Selection of a comprehensive set of IgG clones can typically be obtained within 3-4 weeks, a timescale that is comparable with most prevalent antibody display technologies. The isolated antibodies are well expressed in bacteria and exhibit affinities per binding site in the nanomolar range.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948976     DOI: 10.1038/nprot.2008.176

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  17 in total

Review 1.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  "Inclonals": IgGs and IgG-enzyme fusion proteins produced in an E. coli expression-refolding system.

Authors:  Rahely Hakim; Itai Benhar
Journal:  MAbs       Date:  2009-05-19       Impact factor: 5.857

3.  Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CA.

Authors:  Thierry Wurch; Christel Larbouret; Bruno Robert
Journal:  MAbs       Date:  2009-07-28       Impact factor: 5.857

4.  Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus.

Authors:  Chen Li; Feng Zhang; Hong Lin; Zhong-can Wang; Xin-jian Liu; Zhen-qing Feng; Jin Zhu; Xiao-hong Guan
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

5.  Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge.

Authors:  T J Van Blarcom; C Sofer-Podesta; J Ang; J L Boyer; R G Crystal; G Georgiou
Journal:  Gene Ther       Date:  2010-04-15       Impact factor: 5.250

6.  Characterization of the internal translation initiation region in monoclonal antibodies expressed in Escherichia coli.

Authors:  Erik M Leith; William B O'Dell; Na Ke; Colleen McClung; Mehmet Berkmen; Christina Bergonzo; Robert G Brinson; Zvi Kelman
Journal:  J Biol Chem       Date:  2019-10-11       Impact factor: 5.157

7.  Human anti-EGFL7 recombinant full-length antibodies selected from a mammalian cell-based antibody display library.

Authors:  Feng Li; Yan-Hong Liu; Yan-Wen Li; Qian Ju; Lin Chen; Ping-Li Xie; Yue-Hui Li; Guan-Cheng Li
Journal:  Mol Cell Biochem       Date:  2012-06       Impact factor: 3.396

8.  Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies.

Authors:  Conor Fields; David O'Connell; Sujing Xiao; Gil U Lee; Philippe Billiald; Julien Muzard
Journal:  Nat Protoc       Date:  2013-05-16       Impact factor: 13.491

Review 9.  Unnatural amino acid incorporation in E. coli: current and future applications in the design of therapeutic proteins.

Authors:  Kim Wals; Huib Ovaa
Journal:  Front Chem       Date:  2014-04-01       Impact factor: 5.221

10.  Bacterial cytoplasm as an effective cell compartment for producing functional VHH-based affinity reagents and Camelidae IgG-like recombinant antibodies.

Authors:  Selma Djender; Aurelie Schneider; Anne Beugnet; Ronan Crepin; Klervi Even Desrumeaux; Chiara Romani; Sandrine Moutel; Franck Perez; Ario de Marco
Journal:  Microb Cell Fact       Date:  2014-09-16       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.